| Literature DB >> 32233728 |
Xia Wang1, Chunman Li1, Zeyao Zhu1, Li Yuan2, Wood Yee Chan3, Ou Sha1.
Abstract
The morphogenesis of the mammalian secondary plate is a series of highly dynamic developmental process, including the palate shelves vertical outgrowth, elevation to the horizontal plane and complete fusion in the midline. Extracellular matrix (ECM) proteins not only form the basic infrastructure for palatal mesenchymal cells to adhere via integrins but also interact with cells to regulate their functions such as proliferation and differentiation. ECM remodeling is essential for palatal outgrowth, expansion, elevation, and fusion. Multiple signaling pathways important for palatogenesis such as FGF, TGF β, BMP, and SHH remodels ECM dynamics. Dysregulation of ECM such as HA synthesis or ECM breakdown enzymes MMPs or ADAMTS causes cleft palate in mouse models. A better understanding of ECM remodeling will contribute to revealing the pathogenesis of cleft palate.Entities:
Keywords: ECM; cleft palate; development; morphogenesis; remodeling
Year: 2020 PMID: 32233728 PMCID: PMC7531623 DOI: 10.1080/15476278.2020.1735239
Source DB: PubMed Journal: Organogenesis ISSN: 1547-6278 Impact factor: 2.500
Figure 1.ECM remodeling during palate development.
Cleft palate-related ECM gene mutation in human and mice.
| Gene | Protein | Human Disease | Cleft palate related Clinal features | References | Mouse mutation | Mouse mutation phenotypes | References |
|---|---|---|---|---|---|---|---|
| COL2A1 | Col II | Stickler syndrome type 1 (OMIM 108300) | Cleft palate or bifid uvula, | [ | Transgenic Del1 mice carrying six copies of with COL2A1 ( | Craniofacial ossification retarded; reduced cartilage and bone growth; cleft palate; | [ |
| Kniest dysplasia (OMIM 156550) | Cleft palate | [ | Transgenic mice with targeted inactivation of the COL2A1 gene | No endochondral bone or epiphyseal growth plate in long bones with normal membranous and periosteal skeleton | [ | ||
| Platyspondyly lethal skeletal dysplasia (OMIM 151210) | No cleft palate | [ | ENU induced mutation has a G to A transition at Chromosome 15:97815207, which causes a premature stop codon at amino acid 645 | Cleft palate; shortened nose | [ | ||
| COL11A1 | Col XI | Stickler syndrome type 2 | Cleft palate | [ | Deletion of a cytidine residue about 570 nt downstream of the translation initiation codon in COL11A1 ( | Cleft palate, shortened head and mandible, short limbs, protruding tongue | [ |
| Marshall syndrome | Cleft palate | [ | |||||
| COL11A2 | Col XI | Stickler syndrome type 3: | Cleft palate | [ | Full-length Col11a2 chain was unable to occur because of the presence of premature termination codons | NO cleft palate; | [ |
| Nance-Insley syndrome | Cleft palate | [ | |||||
| FN1 | Fibronectin | NR | Conditional knock out FN1 in cranial neural crest cells | Cleft palate, abnormal cardiac morphogenesis, thymus development defects | [ | ||
| Conditional knock out FN1 in mesoderm cells | Cleft palate, abnormal cardiac morphogenesis, thymus development defects, edema, etc. | [ | |||||
| TNXB | Tenascin-X | Tenascin-X deficiency | Bifid uvula | [ | NR | ||
| ACAN | Aggrecan | NR | Gene mutation in ACAN: | Cleft palate, short limbs, tail, and snout | [ | ||
| VCAN | Versican | NR | Haploinsufficiendy of Versican in Adamts20 mutant mice ( | 65% mutant exhibited cleft palate | [ |
NR, not reported.
ECM molecules expression, function, and remodeling pattern during palatogenesis.
| Expression pattern in the palate | Functional roles during palatogenesis | Remodeling during palatogenesis | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| ECM | Subtype | Location | Detection methods | Species/References | Potential mechanism | Potential function | References | Abnormal remodeling | Detection methods | References |
| Collagens (Col) | Col I | Before palatal elevation: Epithelial basement membrane and palatal mesenchyme (stronger on the nasal side than the oral side in the middle and posterior palate) After palatal elevation: Mesenchyme around the bone | IHC | Mouse[ | Main structure protein | Build up palate infrastructure | [ | Col I is downregulated in the palatal shelves of | IHC | [ |
| Col I and its degrading enzyme MMP 13 are downregulated in T1KO mice | qRT-PCR, WB, IHC | [ | ||||||||
| qRT-PCR, dot blot | Human:[ | Col I synthesis by palatal mesenchymal cells can be induced by TGFβ1 and inhibited by MiR-17-92 clusters | qRT-PCR, WB | [ | ||||||
| Col I synthesis by palatal mesenchymal cells can be induced by TGFβ2 | IHC | [ | ||||||||
| Col II | After the palatal shelf elevation: A few palatal mesenchymal cells | IHC | Mouse:[ | Main cartilage ECM | Palatal mesenchyme osteogenic/chondrogenic fate determination | [ | Enhanced FGF8 signaling causes strong expression of Col II in palatal mesenchymal cells | IHC | [ | |
| Col III | Before palatal elevation: Epithelial basement membrane and palatal mesenchyme | IHC | Mouse:[ | Main structure protein | Build up palate infrastructure | [ | Col III synthesis by palatal mesenchymal cells can be induced by TGFβ1 and inhibited by MiR-17-92 clusters | qRT-PCR, WB | [ | |
| qRT-PCR, dot blot | Human:[ | |||||||||
| Col IV | Epithelial basement membrane | IHC | [ | NR | Col IV expression in the palate is reduced in the Tgf-β3 mutant and can be re-induced by Tgf-β3 | IHC | [ | |||
| Fibronectin | Before palate elevation: Palatal mesenchyme and around MEE, with strong expression around the bulging MEE cells After palate elevation: MES | IHC, ISH | [ | NR | Absent in MEE cells and apical surface in the Tgf-β3 mutant palate and can be re-induced by Tgf-β3; Downregulated in BMP 7 homozygous palate; EDA domain reduced in | IHC, qRT-PCR, WB | [ | |||
| Fibrillins | Fibrillin-1 | Weakly expressed in the palatal mesenchyme only before palatal shelf elevation | IHC | [ | Compose microfibirls and activate Tgf-β | Palatal fusion | [ | NR | ||
| Fibrillin-2 | Before palatal shelf elevation: enriched in the nasal side of palatal mesenchyme After palatal elevation: increased and expanded around MEE cells and in the oral side of palatal mesenchyme | IHC | [ | Inhibited by retinoid acid in a dose-dependent manner | qRT-PCR | [ | ||||
| Tenascins | Tenascin-C | Before palatal elevation: in the mesenchyme close to the nasal and distal surface of the shelf; After palatal elevation: accumulated in the mesenchyme close to the MES | IHC, ISH | [ | NR | Reduced in | qRT-PCR | [ | ||
| Tenascin-W | Before palatal elevation: weekly expressed in the proximal-nasal quadrant of the vertical shelves; After palatal elevation: restricted to the dorsal mesenchyme around the MES, corresponding to the future osteogenic domains of hard palate | IHC, ISH | [ | NR | Diminished in the palatal shelves of | ISH, WB | [ | |||
| Periostin | In the anterior palate (hard palate), periostin is expressed in the mesenchyme on the oral side and part of basal membrane; Intensified around MEE cells in palate fusing process; highly expressed in the entire posterior palate (soft palate) | IHC, ISH | [ | May help to determine soft palate formation | Soft palate formation | [ | TGFβ2 induce periostin production in cultured palate shelves. | IHC | [ | |
| Laminin | Laminin 5 | Discontinuously in the basement membrane and intercellularly in MEE cells | IHC | [ | NR | Becomes continuous in the basement membrane under MEE cells in the Tgf-β3 mutant palate | IHC | [ | ||
| Proteoglycans | CSPGs | CS chains Before the palatal shelf elevation: palatal mesenchyme; During the palatal shelf elevation and the palatal shelf fusion: palatal mesenchyme, transiently upregulated on apical surface of MEE surface; After the palatal shelf fusion: Palatal mesenchyme around the bone | IHC | Mouse:[ | Hold up water; Bind other ECM molecules; Modify TGFβ signaling | Palatal growth, expansion, elevation and adhesion | [ | Reduced in | IHC | [ |
| Versican Before the palatal shelf elevation: Palatal mesenchyme (stronger in nasal/medial and tip than oral/lateral palate) During the palatal shelf elevation and the palatal shelf fusion: Palatal mesenchyme (stronger in nasal/medial and tip than oral/lateral palate, although increased in oral/lateral part), transiently upregulated on apical surface of MEE surface; After the palatal shelf fusion: Decreased in palatal mesenchyme | IHC | [ | Cleaved versican decreased in | IHC | [ | |||||
| Biglycan/Decorin palatal mesenchymal cells at different palate development stages (Decorin restricted to the nasal side); peaked in MEE cells as the palatal shelf adhered | IHC, ISH, qRT-PCR | [ | Disappeared in the MES of TGFβrI kinase inhibitor (SB431542)–treated palates; Decorin are unable to downregulate in the mesenchyme when palatal shelves are elevating; Decorin are downregulated in ectopic Hh signaling palatal shelves | IHC, ISH | [ | |||||
| HSPGs | Before the palatal shelf elevation: Epithelial basement membrane and anterior palatal mesenchyme; During the palatal shelf elevation and the palatal shelf fusion: Epithelial basement membrane (stronger in the oral/lateral side than the nasal/medial side) and the tip of the whole palatal mesenchyme; After the palatal shelf fusion: Epithelial basement membrane (stronger in the oral side than the nasal side); gradually disappear from the palatal mesenchyme; Around vessel basement membrane at all stages | IHC | [ | |||||||
| KSPGs | Lumican Restricted to the nasal mesenchyme of the palate | ISH | [ | Lumican are downregulated in ectopic Hh signaling palatal shelves | ISH | [ | ||||
| HA | Before the palatal shelf elevation: palatal mesenchyme (anterior/mid-part stronger than anterior-most and posterior palate; stronger in the nasal/medial side than the oral/lateral side) | IHC | [ | Retain water | Palatal shelf elevation | [ | Reduced in | IHC | [ | |
MMP associated with palate development.
| Expression pattern in the palate | Mouse mutant associated with cleft palate | |||||||
|---|---|---|---|---|---|---|---|---|
| Extracellular metalloproteinases | Subtype/alternative name | Location | Detection methods | References | ECM substrates during palate development | Mouse mutants | Defects | References |
| MMPs | MMP-1/Collagenase-1 | Unknown | qRT-PCR | [ | NR | NR | ||
| MMP-2/Gelatinase A | Before palate shelf elevation: in the palatal mesenchyme and basement membrane, intensified gradually in the nasal-medial part. | qRT-PCR, IHC, ISH | [ | Cleaves type I collagen | NR | |||
| MMP-3 | Extensively expressed in palatal mesenchyme, transiently upregulated in a subset of nasal palatal epithelial cells. | IHC | [ | NR | NR | |||
| MMP-9/Gelatinase B | Extensively expressed in palatal mesenchyme, transiently upregulated while palatal shelves elevating and fusing. | qRT-PCR, IHC, ISH | Human and mouse:[ | Cleaves laminin | NR | |||
| MMP13 | Before palate shelf elevation: in the palatal mesenchyme and basement membrane, intensified gradually in the nasal-medial part. | IHC, ISH | Mouse[ | NR | NR | |||
| MMP-14/Membrane Type 1-MMP (MT1-MMP) | Highly in MEE | IHC, ISH | [ | NR | Double knockout of MMP-14 and −16 | 80% of double null of MMP-14 and −16 have a cleft palate | [ | |
| MMP-16/Membrane Type 3-MMP (MT3-MMP) | Unknown | NR | Double knockout of MMP-14 and −16 | 80% of double null of MMP-14 and −16 have a cleft palate | [ | |||
| MMP-25 | The tips of palatal epithelium and mesenchyme | IHC, ISH | [ | NR | NR | |||
| TIMPs | TIMP-1 | Before palate shelf elevation: in the central and maxillary region of palatal mesenchyme | IHC | [ | NR | NR | ||
| TIMP-2 | Before palate shelf elevation: in the central and maxillary region of palatal mesenchyme | IHC | [ | NR | NR | |||
| TIMP-3 | Palatal epithelium, transiently expressed in mid-oral and ventral-medial mesenchyme. | IHC | [ | NR | NR | |||
| TIMP-4 | Oral mucosa | IHC | [ | NR | NR | |||
| ADAMTS | ADAMTS9 | Palatal capillary endothelium | ISH | [ | Versican | Haploinsufficiendy of Adamts9 in Adamts20 mutant mice ( | Complete cleft palate | [ |
| ADAMTS20 | Palatal mesenchyme | ISH | [ | |||||
NR, not reported.
IHC, immunohistochemical staining.
ISH, in situ hybridization.